Comparative Pharmacology
Head-to-head clinical analysis: SULFOSE versus TERFONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFOSE versus TERFONYL.
SULFOSE vs TERFONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
TERFONYL is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication.
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
2 g intravenously every 12 hours over 24 hours for susceptible infections.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Renal excretion accounts for 70-90% of elimination as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal excretion constitutes 10-30%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic